-
May 20, 2025 Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
-
May 13, 2025 Apotex announces grant to Foundation for Mother and Child Health to promote maternal health with CAD $100,000 in annual funding
-
May 13, 2025 Apotex announces $100,000 in annual funding to advance maternal and infant health in Mexico
-
May 13, 2025 Apotex announces grant to Healthy Mothers, Healthy Babies Coalition of Broward County to promote maternal health with $242,000 in annual funding
-
May 13, 2025 Apotex announces launch of the Apotex Global Health Access Fund to promote health equity with $250,000 in annual funding to the Rexdale Community Health Centre
-
May 7, 2025 Apotex announces expansion of licensing agreement with Formosa Pharmaceuticals to Mexico for commercialization of clobetasol propionate ophthalmic suspension for the treatment of inflammation and pain following ocular surgery
-
Feb 3, 2025 Apotex enters the growing Canadian health and wellness sector through the acquisition of CanPrev, a leading Canadian natural health company
-
Aug 7, 2024 Apotex expands ophthalmic franchise through the acquisition of Canadian rights to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%), a novel steroid for ophthalmology
-
Jul 3, 2024 Apotex Further Expands Oncology Franchise Through the Acquisition of Canadian Rights to Toripalimab
-
Jun 3, 2024 Apotex Completes Acquisition of Searchlight, a leading Canadian-based Specialty Innovative Branded Pharmaceutical Company
-
Apr 2, 2024 Apotex to Acquire Searchlight Pharma, a Canadian Specialty Branded Pharmaceutical Leader
-
Feb 16, 2024 Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
-
Apr 19, 2023 Apotex Receives FDA’s Drug Shortage Assistance Award
-
Apr 3, 2023 SK Capital completes acquisition of Apotex, a global leader in affordable pharmaceuticals
-
Sep 28, 2022 SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals
-
Jul 20, 2022 First Generic Alternative to Eliquis® Now Available in Canada
-
May 17, 2022 Apotex Launches Affordable Generic Option to Treat Relapsing Remitting Multiple Sclerosis
-
Apr 12, 2022 Apotex Corp. Launches Generic of Abraxane® in the United States
-
Feb 2, 2021 Apotex Corp. Issues Voluntary Nationwide Recall of Enoxaparin Sodium Injection, USP Due to Mislabeling of Syringe Barrel Measurement Markings
-
May 26, 2020 APOTEX CORP. DONATES CRITICAL MEDICINES IN THE FIGHT AGAINST COVID-19
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
May 20, 2025
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. "As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex.
-
May 13, 2025
Apotex announces grant to Foundation for Mother and Child Health to promote maternal health with CAD $100,000 in annual funding
Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, yesterday announced a grant through the Apotex Global Health Access Fund to the Foundation for Mother and Child Health ("FMCH") in Mumbai, India to support programs that promote maternal health and address child malnutrition.
-
May 13, 2025
Apotex announces $100,000 in annual funding to advance maternal and infant health in Mexico
Mexico City - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced a grant through the Apotex Global Health Access Fund to Vida y Familia México, I.A.P. ("VIFAC") to support programs that promote maternal and child health and address health disparities.